Baltic Sea Region is frontrunner for eHealth

A very fruitful panel discussion took place on 14th of June within the 8th Annual Forum of the EU Strategy for the Baltic Sea Region in Berlin. Organised by the BFCC project it proved again that the countries of the Baltic Sea Region are frontrunners for eHealth, esp. Estonia and Sweden. Prof. Wolfgang Hoffmann from the University Medicine Greifswald claimed: "The benefit of eHealth applications should be more communicated to the citizens. In many countries, the citizens themselves have become drivers for eHealth." The results of the discussion will be considered in the 'Digital Health Society Declaration', which will be published during the Estonian EU presidency in the second half of this year. Furthermore, these results will contribute to the sustainability strategy of the BFCC project. The organisational and financial concept will ensure the future of Baltic Fracture Competence Centre beyond the project lifecycle. More about the 8th Annual Forum.

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …